Submission of Standalone audited financial result of the company along with statement of assets and liabilities and cash flow.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
KMS Medisurgi Limited submitted its audited standalone financial results for FY25 (year ended March 31, 2025). Revenue from operations was Rs. 1,393.86 lakhs vs Rs. 1,388.46 lakhs in FY24 — virtually flat (~0.4% growth). Profit After Tax came in at Rs. 43.98 lakhs vs Rs. 45.39 lakhs last year, a marginal dip of about 3%, with EPS at Rs. 1.33 vs Rs. 1.38. Net worth improved to Rs. 808.58 lakhs from Rs. 766.25 lakhs. Operating cash flow was healthy at Rs. 73.79 lakhs. The statutory auditor issued a Qualified Opinion, flagging two repetitive issues: (1) post-employment benefits (gratuity) are accrued based on an LIC group gratuity statement rather than an actuarial valuation as required by AS-15, and (2) stock records reconciliation is pending, leaving closing inventory of Rs. 252.24 lakhs unverified by the auditor.
Flat revenue and a slight dip in PAT signal sluggish core business performance. The repeated qualified opinion — especially around unreconciled inventory of Rs. 252 lakhs — is a governance and internal-control red flag that investors should track, as future adjustments could impact reported earnings.